Smokeless tobacco does increase the risk of heart disease, though the effect is smaller than cigarette smoking. The size of the risk depends on the type of product and how it’s used. Case-control studies from multiple countries show that people who chew tobacco have roughly double the odds of experiencing a serious coronary event compared to non-users, while large prospective studies in Europe put the increased risk of fatal coronary heart disease at around 13%. The picture is nuanced, but the overall direction is clear: smokeless tobacco is not safe for your heart.
How Much Risk Smokeless Tobacco Adds
The most striking numbers come from the INTERHEART study, a large international case-control study that found tobacco chewers had 2.23 times the odds of a non-fatal heart attack compared to non-users, even after adjusting for smoking, blood pressure, diabetes, and obesity. That’s a meaningful jump in risk for a product many people assume is harmless because it doesn’t involve smoke.
Meta-analyses that pool together many prospective studies paint a somewhat more modest picture. Across European studies, the relative risk of fatal coronary heart disease among smokeless tobacco users was 1.13, meaning a 13% increase. In Asian countries, where chewing tobacco products tend to contain different ingredients, the risk was higher at 1.26, or a 26% increase. A separate global meta-analysis found the overall summary risk for coronary heart disease was 1.05, which was not statistically significant, but the subset looking only at fatal outcomes showed a risk of 1.10 that bordered on significance. The variation in these numbers reflects real differences in products, populations, and study designs rather than a simple yes-or-no answer.
Stroke Risk Is Also Elevated
Smokeless tobacco’s effects on the heart extend to the brain’s blood supply. A pooled analysis of studies examining fatal stroke found an odds ratio of 1.40 among smokeless tobacco users, a 40% increase in risk. That’s actually a larger effect size than what most studies find for heart attacks, making stroke one of the more concerning cardiovascular consequences of long-term use.
Research from a Swedish cohort studying snus (a moist tobacco product popular in Scandinavia) found that even this relatively “cleaner” product was linked to an increased risk of stroke among people who had never smoked cigarettes. So even in populations using products with fewer toxic additives, the stroke signal persists.
What Smokeless Tobacco Does Inside Your Body
The cardiovascular harm from smokeless tobacco traces back primarily to nicotine, which is absorbed through the lining of the mouth in large quantities. A study measuring the immediate effects of oral snuff found that blood nicotine levels nearly quadrupled after use, jumping from about 2.8 to 10.4 nanograms per milliliter. That nicotine surge triggers a cascade of changes that stress the cardiovascular system.
Blood pressure rises by an average of 10 mmHg, and heart rate jumps by about 16 beats per minute. The body also releases roughly 50% more epinephrine (adrenaline) from the adrenal glands. Normally, when blood pressure rises, the body compensates by relaxing blood vessels and dialing down nerve signals to the heart. That safety mechanism doesn’t kick in properly with smokeless tobacco. Blood vessels stay constricted even as pressure climbs, which is why researchers describe it as a “powerful autonomic and hemodynamic stimulus.”
Beyond these immediate spikes, smokeless tobacco drives chronic inflammation. Users have significantly higher levels of C-reactive protein (CRP), a blood marker that signals inflammation throughout the body. One comparative study found that smokeless tobacco users had a mean CRP level more than four times higher than non-users (0.77 vs. 0.18 mg/dL). Chronic inflammation damages blood vessel walls over time and accelerates the buildup of fatty plaques, the underlying process behind most heart attacks and strokes.
How It Compares to Cigarette Smoking
Smokeless tobacco is less dangerous for the heart than cigarettes, but “less dangerous” is not the same as safe. Cigarette smoking roughly doubles or triples the risk of coronary heart disease depending on how heavily someone smokes. Smokeless tobacco’s effect on fatal coronary disease, at around 10 to 26% increased risk in most analyses, is considerably smaller. The difference makes sense because cigarette smoke delivers carbon monoxide, fine particulate matter, and oxidative chemicals that directly damage arteries in ways that nicotine alone does not.
Still, the gap narrows for certain outcomes. The 40% increased risk of fatal stroke among smokeless tobacco users is not dramatically different from some smoking-related stroke estimates. And for people who already have heart disease, the stakes are higher. The American Heart Association’s 2024 policy statement notes that smokeless oral nicotine products are associated with increased mortality risk specifically in people with existing ischemic heart disease or cerebrovascular disease.
Not All Products Carry the Same Risk
The cardiovascular risk from smokeless tobacco varies considerably depending on what’s in the product. Swedish snus, which is manufactured under strict regulations and has lower levels of certain harmful chemicals, appears to carry less heart risk than the chewing tobacco and gutka products common in South and Southeast Asia. A large Swedish prospective study found that current snus use was not significantly associated with cardiovascular death after full statistical adjustment (hazard ratio of 1.02). By contrast, studies from the United States have found higher cardiovascular mortality among men using chewing tobacco or snuff.
Products used in South Asia often contain added ingredients like slaked lime, areca nut, and various flavorings that may amplify cardiovascular harm. This helps explain why Asian studies consistently show larger risk increases than Scandinavian ones. If you use smokeless tobacco, the specific product matters, but no version has been proven completely free of cardiovascular effects.
What Happens When You Quit
Quitting smokeless tobacco produces some rapid improvements in cardiovascular function, along with some surprising short-term complications. A Swedish cohort study tracked snus users for 12 weeks after they stopped. Heart rate dropped by nearly 6 beats per minute within the first week, a sign that the constant nicotine-driven stimulation of the heart was easing. Diastolic blood pressure (the bottom number) also fell by about 2.5 mmHg in that first week.
The longer-term picture was more complicated. By week 12, systolic blood pressure (the top number) had actually risen by 3.7 mmHg on average, and participants gained about 1.8 kilograms (roughly 4 pounds). Blood sugar markers also crept up slightly. These changes likely reflect the metabolic effects of nicotine withdrawal: nicotine suppresses appetite and mildly boosts metabolism, so removing it can temporarily worsen some risk factors even as others improve. Inflammatory markers (CRP) spiked at 4 weeks but largely normalized by 12 weeks.
These findings don’t mean quitting is bad for your heart. They mean the body goes through an adjustment period, and some health metrics temporarily move in the wrong direction before stabilizing. The long-term trajectory of quitting any tobacco product is consistently toward lower cardiovascular risk, but the first few months can involve trade-offs that are worth being aware of, particularly around weight management.